

...The **Key** to Eradicate Polio

Join the War to wipe out Polio from the World.... Switch from trivalent to bivalent Oral Polio Vaccine (**BIOPOLIO® B1/3**)

Why Switch?

- Currently used trivalent OPV (tOPV) has three vaccine strains of polio virus (type 1, 2 & 3)
- All circulating wild polio viruses belong to type 1 & 3
- Last reported case of wild polio virus type 2 was in 1999 in India
- Continued use of type 2 strain in vaccine carries the risk of Vaccine Derived Polio Virus infections (VDPV)
- Since 2009, 97% of all VDPVs were due to type 2 virus ¹
- WHO recommends worldwide cessation of type 2 component OPV use

Advantages of bivalent Oral Polio (bOPV) Vaccine



- No type 2 strain
- Preferred oral vaccine in the lead up to complete IPV adaption
- NO interference with immune response to type 1 & 3; lesser number of doses required for herd immunity ¹
- Confers higher seroconversion for poliovirus type 1 & 3 ²
- More effective than tOPV and as good as mOPV ³
- Recommended for Routine Immunization Activities (RIAs)
- Integrated into the Global Polio Eradication Initiative 2010-2012



Study Results:



Immunogenicity & Safety Proven thro' Bharat Biotech's Pivotal Phase III Clinical Trials on **BIOPOLIO B1/3**⁴

Immunogenicity



Safety

The most common adverse events reported were fever, cough, cold & vomiting when treated symptomatically. All events were resolved within 24-48 hours.



BIOPOLIO B1/3 - WHO Prequalified Vaccine

- More than 2 billion doses sold Worldwide
- Clinically Proven Immunogenicity & Safety
- No shedding of Vaccine Virus



All new flip off seal offers hassle free administration

For more information please feel free to email us on info@bharatbiotech.com



Genome Valley Hyderabad -500 078. T.S. India.
www.bharatbiotech.com

1. Background and Technical Rationale for Introduction of One dose of Inactivated Polio Vaccine (IPV) in Routine Immunization Schedule Oct, 2015
2. John TJ. Immunisation against polioviruses in developing countries. Rev Med Virol. 1993; 3:149-160
3. Sutter RW et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet. 2010; 376 (9753):1682-1688
4. Data on file